154 related articles for article (PubMed ID: 18438661)
1. Treatment efficacy of combined biphosphonates and 186Re-HEDP treatment in cancer patients with bone metastases.
Koutsikos J; Leondi A
Eur J Nucl Med Mol Imaging; 2008 Jul; 35(7):1392-3; author reply 1394-5. PubMed ID: 18438661
[No Abstract] [Full Text] [Related]
2. [Pain therapy with rhenium-186 HEDP in multiple bone metastases].
Palmedo H; Bender H; Schomburg A; Grünwald F; Schöneich G; Zamorra P; Reichmann K; Dierke-Dzierzon C; Mallmann P; Biersack HJ
Nuklearmedizin; 1996 Apr; 35(2):63-7. PubMed ID: 8721578
[TBL] [Abstract][Full Text] [Related]
3. Re-186 HEDP treatment in breast cancer patients with bone metastases.
Koutsikos J; Leondi A
J Natl Med Assoc; 2008 Apr; 100(4):447. PubMed ID: 18481487
[No Abstract] [Full Text] [Related]
4. Hormone refractory prostatic cancer: the role of radiolabelled diphosphonates and growth factor inhibitors.
Scher HI; Curley T; Yeh S; Tong W; O'Moore PV; Larson S
Adv Exp Med Biol; 1992; 324():115-29. PubMed ID: 1283494
[No Abstract] [Full Text] [Related]
5. Introduction of a new semi-quantitative index with predictive implications in patients with painful osseous metastases after (186)Re-HEDP therapy.
Zafeirakis A; Zissimopoulos A; Baziotis N; Limouris GS
Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):91-102. PubMed ID: 21068716
[TBL] [Abstract][Full Text] [Related]
6. Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re-186-HEDP.
De Klerk JM; Zonnenberg BA; Blijham GH; Van Het Schip AD; Hoekstra A; Han SH; Quirijnen JM; Van Dijk A; Van Rijk PP
Anticancer Res; 1997; 17(3B):1773-7. PubMed ID: 9179233
[TBL] [Abstract][Full Text] [Related]
7. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases.
Liepe K; Kotzerke J
Nucl Med Commun; 2007 Aug; 28(8):623-30. PubMed ID: 17625384
[TBL] [Abstract][Full Text] [Related]
8. A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone.
O'Sullivan JM; Norman AR; McCready VR; Flux G; Buffa FM; Johnson B; Coffey J; Cook G; Treleaven J; Horwich A; Huddart RA; Parker CC; Dearnaley DP
Eur J Nucl Med Mol Imaging; 2006 Sep; 33(9):1055-61. PubMed ID: 16572306
[TBL] [Abstract][Full Text] [Related]
9. 186Re-etidronate. Efficacy of palliative radionuclide therapy for painful bone metastases.
Han SH; De Klerk JM; Zonnenberg BA; Tan S; Van Rijk PP
Q J Nucl Med; 2001 Mar; 45(1):84-90. PubMed ID: 11456380
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer.
Kolesnikov-Gauthier H; Carpentier P; Depreux P; Vennin P; Caty A; Sulman C
J Nucl Med; 2000 Oct; 41(10):1689-94. PubMed ID: 11037999
[TBL] [Abstract][Full Text] [Related]
11. Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease.
Brenner W; Kampen WU; Kampen AM; Henze E
J Nucl Med; 2001 Feb; 42(2):230-6. PubMed ID: 11216521
[TBL] [Abstract][Full Text] [Related]
12. [Clinical value of combined therapy with 188Re-HEDP and pamidronate in breast cancer with bone metastasis].
Liang JG; Jiang NY; DU JQ; Lu XP; Liu XG; Chen SX
Zhonghua Zhong Liu Za Zhi; 2005 Mar; 27(3):180-2. PubMed ID: 15946573
[TBL] [Abstract][Full Text] [Related]
13. Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer.
de Klerk JM; Zonnenberg BA; van het Schip AD; van Dijk A; Han SH; Quirijnen JM; Blijham GH; van Rijk PP
Eur J Nucl Med; 1994 Oct; 21(10):1114-20. PubMed ID: 7530199
[TBL] [Abstract][Full Text] [Related]
14. The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain.
Liepe K; Runge R; Kotzerke J
J Cancer Res Clin Oncol; 2005 Jan; 131(1):60-6. PubMed ID: 15449184
[TBL] [Abstract][Full Text] [Related]
15. Palliative therapy with rhenium-186-HEDP for bone metastases of breast cancer.
Guerra UP; Englaro E; Cattaruzzi E
Tumori; 1997; 83(2):560-2. PubMed ID: 9226021
[No Abstract] [Full Text] [Related]
16. Treatment of painful bone metastases in prostate and breast cancer patients with the therapeutic radiopharmaceutical rhenium-188-HEDP. Clinical benefit in a real-world study.
Lange R; Overbeek F; de Klerk JM; Pasker-de Jong PC; van den Berk AM; Ter Heine R; Rodenburg CJ; Kooistra A; Hendrikse NH; Bloemendal HJ
Nuklearmedizin; 2016 Sep; 55(5):188-95. PubMed ID: 27443809
[TBL] [Abstract][Full Text] [Related]
17. EANM procedure guidelines for treatment of refractory metastatic bone pain.
Silberstein EB; Taylor AT;
Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):BP7-11. PubMed ID: 12723557
[No Abstract] [Full Text] [Related]
18. Radiation safety considerations for the bone seeking radiopharmaceuticals. 89SrCl2, 186Re-HEDP and 153Sm-EDTMP.
Lam MG; Hoekstra A; de Klerk JM; van Rijk PP; Zonnenberg BA
Nuklearmedizin; 2009; 48(1):37-43. PubMed ID: 19212610
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases].
Liepe K; Franke WG; Kropp J; Koch R; Runge R; Hliscs R
Nuklearmedizin; 2000 Sep; 39(6):146-51. PubMed ID: 11057405
[TBL] [Abstract][Full Text] [Related]
20. Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients.
Sciuto R; Festa A; Pasqualoni R; Semprebene A; Rea S; Bergomi S; Maini CL
Breast Cancer Res Treat; 2001 Mar; 66(2):101-9. PubMed ID: 11437096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
